Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06488170 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 24, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Jan 2025 to Jan 2026 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 50 to confirmed 42 · Study sites: 4 to 7v2 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 50 to confirmed 42
    • Study sites: 4 to 7
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Almirall, S.A.
15 trials monitored
See all monitored trials
Psoriasis
420 trials monitored
See 17 trials at risk
The main purpose of this study to investigate the relationship between clinical symptoms and quality of life (QoL) in participants who receive Tildrakizumab in the frame of clinical routine for the treatment of moderate to severe plaque psoriasis in accordance with the summary of product characteristics (SmPC).
Trial Details
NCT Number NCT06488170
Lead Sponsor Almirall, S.A.
Conditions Plaque Psoriasis
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov